+ Watch PCRX
on My Watchlist
exparel is a game changing product
good product with expanding indications
Novel delivery mechanism for generic bipuvicaine that enables 72-hour post-surgery pain relief with a single shot, minimizing the need for opioids. Zero competition and huge target market. Potential to double in 18-24 months.
Their single product, an injectable, long lasting pain reliever, is going to revolutionize post surgical patient care.
Driven up too high on excitement over one drug--which itself will not bring these guys into profitability.
This drug will enable providers to send their patients home with minimal narcotics, providing days of minimal post-operative pain, without the untoward complications.
Nda approval for exparel
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions